Efficacy and Safety of Sintilimab Plus Bevacizumab in Metastatic Nasopharyngeal Carcinoma After Failure of Platinum-based Chemotherapy: An Open-label Phase II Study

Sponsor
XIANG YANQUN
Study ID
NCT04872582
Phase
PHASE2
Status
Unknown

Conditions

  • Chemotherapy Effect
  • Metastatic Nasopharyngeal Carcinoma

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

To evaluate the efficacy and safety of PD-1 immune checkpoint inhibitor combined with bevacizumab in the treatment of metastatic nasopharyngeal carcinoma after failure of platinum-based chemotherapy.

Key Dates

First listed
May 4, 2021
Start date
Jul 29, 2021
Status verified
Feb 2023
Primary completion
Jan 4, 2023
Completion
Oct 31, 2024

Study Design

Enrollment
33 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: PD-1 immune checkpoint inhibitor combined with bevacizumab

Primary Outcome Measure

objective response rate (ORR) [ Time Frame: 2 years ]

Related Studies